Enovis Co. (NYSE:ENOV) Shares Bought by Quantinno Capital Management LP

Quantinno Capital Management LP boosted its holdings in shares of Enovis Co. (NYSE:ENOV - Free Report) by 363.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 28,804 shares of the company's stock after buying an additional 22,593 shares during the quarter. Quantinno Capital Management LP owned 0.05% of Enovis worth $1,240,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ENOV. Cetera Advisors LLC purchased a new position in shares of Enovis in the 1st quarter valued at about $239,000. SG Americas Securities LLC lifted its stake in Enovis by 93.8% in the second quarter. SG Americas Securities LLC now owns 20,634 shares of the company's stock worth $933,000 after acquiring an additional 9,985 shares during the last quarter. Envestnet Portfolio Solutions Inc. lifted its stake in Enovis by 44.0% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 9,033 shares of the company's stock worth $408,000 after acquiring an additional 2,761 shares during the last quarter. Tributary Capital Management LLC increased its position in shares of Enovis by 20.9% in the 2nd quarter. Tributary Capital Management LLC now owns 409,190 shares of the company's stock valued at $18,495,000 after purchasing an additional 70,819 shares during the last quarter. Finally, Institute for Wealth Management LLC. acquired a new stake in shares of Enovis in the 2nd quarter valued at $241,000. Hedge funds and other institutional investors own 98.45% of the company's stock.

Enovis Stock Performance

Shares of NYSE ENOV traded down $0.78 during trading hours on Friday, reaching $46.14. The stock had a trading volume of 496,454 shares, compared to its average volume of 580,633. The firm has a 50-day moving average of $44.26 and a 200-day moving average of $44.66. The firm has a market cap of $2.58 billion, a price-to-earnings ratio of -21.07 and a beta of 1.94. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. Enovis Co. has a fifty-two week low of $38.27 and a fifty-two week high of $65.03.

Enovis (NYSE:ENOV - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.62 by $0.11. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The business had revenue of $505.22 million for the quarter, compared to analyst estimates of $504.44 million. During the same period last year, the firm posted $0.56 earnings per share. The company's revenue for the quarter was up 21.0% compared to the same quarter last year. Equities research analysts predict that Enovis Co. will post 2.79 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Evercore ISI lowered their target price on shares of Enovis from $62.00 to $58.00 and set an "outperform" rating for the company in a research note on Tuesday, October 1st. JMP Securities began coverage on Enovis in a report on Thursday, October 3rd. They set an "outperform" rating and a $62.00 price target for the company. Finally, Needham & Company LLC reissued a "buy" rating and set a $65.00 target price on shares of Enovis in a research report on Thursday, November 7th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, Enovis currently has an average rating of "Moderate Buy" and a consensus target price of $67.00.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.